Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lomitapide
Drug ID BADD_D01311
Description Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Indications and Usage Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
Marketing Status approved; investigational
ATC Code C10AX12
DrugBank ID DB08827
KEGG ID D09637
MeSH ID C473731
PubChem ID 9853053
TTD Drug ID D0H8VY
NDC Product Code Not Available
UNII 82KUB0583F
Synonyms BMS201038 | BMS-201038 | BMS 201038 | lomitapide | Juxtapid | AEGR 733 | AEGR733 | AEGR-733
Chemical Information
Molecular Formula C39H37F6N3O2
CAS Registry Number 182431-12-5
SMILES C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C (=O)NCC(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gait disturbance17.02.05.016; 08.01.02.002; 15.03.05.013--
Gamma-glutamyltransferase increased13.03.04.024--
Gastric dilatation07.02.02.002--Not Available
Gastritis07.08.02.0010.000058%
Gastrooesophageal reflux disease07.02.02.0030.000469%
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.0010.001287%Not Available
Gastrointestinal infection07.19.02.005; 11.01.07.012--Not Available
Gastrointestinal pain07.01.05.0050.000047%
Gout14.09.01.001; 15.01.06.0010.000156%Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemorrhoids24.10.02.002; 07.15.03.0010.000073%
Headache17.14.01.0010.000927%
Hepatic steatosis14.08.04.005; 09.01.07.0030.000126%Not Available
Hepatomegaly09.01.05.001--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hernia08.01.04.0010.000084%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.0030.000218%
Hypoaesthesia23.03.03.081; 17.02.06.0230.000193%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.000021%
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.0100.000328%
Insomnia19.02.01.002; 17.15.03.0020.000422%
International normalised ratio abnormal13.01.02.029--Not Available
International normalised ratio increased13.01.02.008--
Joint stiffness15.01.02.0030.000084%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene